Compare SAMG & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | TKNO |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.5M | 111.9M |
| IPO Year | 2012 | 2021 |
| Metric | SAMG | TKNO |
|---|---|---|
| Price | $15.23 | $2.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.2K | ★ 339.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.54% | N/A |
| EPS Growth | N/A | ★ 50.86 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $91,358,000.00 | $37,745,000.00 |
| Revenue This Year | $3.37 | $8.64 |
| Revenue Next Year | $10.62 | $9.73 |
| P/E Ratio | $27.78 | ★ N/A |
| Revenue Growth | N/A | ★ 2.89 |
| 52 Week Low | $13.23 | $1.91 |
| 52 Week High | $18.60 | $7.48 |
| Indicator | SAMG | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | N/A |
| Support Level | $14.74 | N/A |
| Resistance Level | $15.41 | N/A |
| Average True Range (ATR) | 0.33 | 0.00 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 78.99 | 0.00 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.